Cancer Research: A Supercomputing Perspective

By Aaron Dubrow

May 31, 2017

Cancer, the second-leading cause of death in the U.S. after heart disease, kills more than 500,000 citizens per year, including about 2,000 children.

In 2016, then Vice President Joe Biden launched the Cancer Moonshot, saying: “I know that we can help solidify a genuine global commitment to end cancer as we know it today —  and inspire a new generation of scientists to pursue new discoveries and the bounds of human endeavor.”

The importance of high performance computing (HPC) in cancer research was recognized by the Cancer Moonshot Task Force report, and by then Vice President Joe Biden and Energy Secretary Ernie Monitz.

“Supercomputers are key to the Cancer Moonshot,” Monitz wrote. “These exceptionally high-powered machines have the potential to greatly accelerate the development of cancer therapies by finding patterns in massive datasets too large for human analysis. Supercomputers can help us better understand the complexity of cancer development, identify novel and effective treatments, and help elucidate patterns in vast and complex data sets that advance our understanding of cancer.”

With complex, non-linear signaling networks, multiscale dynamics from the quantum to the macro level, and giant, complex datasets of patient responses, cancer is quite possibly the ultimate in HPC problems.

“What could be more complicated and more important?” said J. Tinsley Oden, a computational researcher at The University of Texas at Austin applying uncertainty quantification to cancer treatment predictions. “At each step, it has the most complex features. It is really a garden of rich, important problems that are in the path of many of the developments that we’ve been working on for years.”

Infographic depicts TACC’s multi-domain approach to fighting cancer — click to expand

Hundreds of oncologists, biologists and computer scientists use the HPC systems at the Texas Advanced Computing Center (TACC) to understand the fundamental nature of cancer biology and to improve cancer treatments. Their work addresses a range of cancers types and treatment modalities, and spans applied or fundamental research.

Though diverse in their specific targets, the approaches they use can be loosely grouped into seven broad methodologies: molecular simulation; bioinformatics; mathematical modeling; computational treatment planning; quantum calculation; clinical trial design; and machine learning. The following sections describe and provide examples of each.

Molecular Simulations

Simulating protein and drug interactions at the molecular level enables scientists to understand the mechanics of cancer to design more effective treatments.

For Rommie Amaro, professor of Chemistry and Biochemistry at the University of California, San Diego, this means uncovering new pockets in tumor protein 53 (p53) — “the guardian of the genome” — which plays a crucial role in conserving the stability of DNA and preventing mutations.

The model of full-length p53 protein bound to DNA as a tetramer. The surface of each p53 monomer is depicted with a different color. [Courtesy: Özlem Demir, University of California, San Diego]
In approximately 50 percent of all human cancers, p53 is mutated and rendered inactive, therefore, reactivating mutant p53 using small molecules has been a long-sought-after anticancer therapeutic strategy.

In September 2016, writing in the journal Oncogene, Amaro reported results of the largest atomic-level simulation of the p53 to date — comprising more than 1.5 million atoms. The simulations, enabled by the Stampede supercomputer at TACC, helped identify new binding sites on the surface of the protein that could potentially reactivate p53.

“When most people think about cancer research they probably don’t think about computers,” she said. “But biophysical models are getting to the point where they have a great impact on the science.”

Virtual drug screening is another important HPC application for cancer research. Shuxing Zhang, professor of experimental therapeutics at MD Anderson Cancer Center, used molecule simulations on TACC’s Lonestar5 system to screen 1,448 Food and Drug Administration-approved small molecule drugs to determine which had the molecular features needed to bind and inhibit TNIK — an enzyme that plays a key role in cell signaling in colon cancer.

Zhang discovered that mebendazole, an FDA-approved drug that fights parasites, could effectively bind to TNIK and inhibit its enzymatic activity. He reported his results in Nature Scientific Reports in September 2016.

“Such advantages render the possibility of quickly translating the discovery into a clinical setting for cancer treatment in the near future,” Zhang wrote.

Bioinformatics

The human genome consists of three billion base pairs, so identifying single mutations by sight simply isn’t possible. For that reason, the field of bioinformatics — which uses computing and software to identify patterns and differences in biological data — has been an enormous boon for cancer researchers.

But bioinformatics is more than simple, one-to-one pattern matching.

A heat map showing differences in gene expression between primary tumors and cultured cell lines. Each row is a gene and each column is a tumor or cell sample. In the heat map, red indicates high expression and blue indicates low expression. NHA refers to normal human astrocytes, a star-shaped glial cell of the central nervous system. [Courtesy: Amelia Weber Hall, Iyer lab]
“When you move into multi-dimensional, time-series, or population-level studies, the algorithms can get a lot more computationally intensive,” said Matt Vaughn, TACC’s Director of Life Sciences Computing. “This requires resources like those at TACC, which help large numbers of researchers explore the complexity of cancer genomes by providing elastic, large-scale computing capability.”

For Vishy Iyer, a molecular biologist at The University of Texas at Austin (UT Austin), and his collaborators, access to TACC’s Stampede supercomputer helps them mine reams of data from The Cancer Genome Atlas to identify genetic variants and subtle correlations that affect gene expression in tumors.

“TACC has been vital to our analysis of cancer genomics data, both for providing the necessary computational power and the security needed for handling sensitive patient genomic datasets,” Iyer said.

In February 2016, Iyer and a team of researchers from UT Austin and MD Anderson Cancer Center reported in Nature Communications on a genome-wide transcriptome analysis of the two types of cells that make up the prostate gland. They identified cell-type-specific gene signatures that were associated with aggressive subtypes of prostate cancer and adverse clinical responses.

“This knowledge can be helpful in the development of more targeted therapies that seek to eliminate cancer at its origin,” Iyer said.

Using a similar methodology, Iyer and a team of researchers from UT Austin and the National Cancer Institute identified a transcription factor associated with an aggressive type of lymphoma that is highly correlated with poor therapeutic outcomes. They published their results in the Proceedings of the National Academy of Sciences in January 2016.

Whereas Iyer, an experienced HPC user, develops custom tools for his analyses, a much larger number of researchers access Stampede and comparable systems through scientific gateways. One prominent gateway is Galaxy, an open source bioinformatics platform that serves 30,000 researchers and runs more than 3,000 compute jobs a day.

Since 2014, TACC has powered the data analyses for a large percentage of Galaxy users, allowing researchers to solve tough problems in cases where their personal computer or campus cluster is not sufficient. Of those researchers, a significant subset use the site to analyze cancer genomes.

“Galaxy can be used to identify tumor mutations that drive cancer growth, find proteins that are overexpressed in a tumor, as well as for chemo-informatics and drug discovery,” said Jeremy Goecks, Assistant Professor of Biomedical Engineering and Computational Biology at Oregon Health and Science University and one of Galaxy’s principal investigators.

Goecks estimates that hundreds of researchers each year use the platform for cancer research, himself included. Because cancer patient data is closely protected, the bulk of this usage involves either publically available cancer data, or data on cancer cell lines – immortalized cells that reproduce in the lab and are used to study how cancer reacts to different drugs or conditions.

“This is an ideal marriage of TACC having tremendous computing power with scalable architecture and Galaxy coming along and saying, we’re going to go the last mile and make sure that people who can’t normally use this hardware are able to.”

Mathematical Modeling

While some researchers believe bioinformatics will rapidly advance the understanding and treatment of cancer, others think a better approach is to mathematize cancer: to uncover the fundamental formulas that represent how cancer, in its varied forms, behaves.

At the Center for Computational Oncology at UT Austin, researchers are developing complex computer models to predict how cancer will progress in a specific individual.

Each factor involved in the tumor response — whether it is the speed with which chemotherapeutic drugs reach the tissue or the degree to which cells signal each other to grow — is characterized by a mathematical equation that captures its essence. These models are combined and parameterized and initialized with patient-specific data.

In April 2017, writing in the Journal of The Royal Society Interface, Thomas Yankeelov and collaborators at UT Austin and Vanderbilt University, showed that they can predict how brain tumors (gliomas) will grow in mice with greater accuracy than previous models by including factors like the mechanical forces acting on the cells and the tumor’s cellular heterogeneity.

To develop and implement their mathematically complex models, the center’s scientists use TACC’s supercomputers, which enable them to solve bigger problems that they otherwise could and reach solutions far faster.

Recently, the group has begun a clinical study to predict, after one treatment, how an individual’s cancer will progress, and use those predictions to plan the future course of treatment.

“There are not enough resources or patients to sort this problem out because there are too many variables. It would take until the end of time,” Yankeelov said. “But if you have a model that can recapitulate how tumors grow and respond to therapy, then it becomes a classic engineering optimization problem. ‘I have this much drug and this much time. What’s the best way to give it to minimize the number of tumor cells for the longest amount of time?’”

Computing at TACC helps Yankeelov accelerate his research. “We can solve problems in a few minutes that would take us three weeks to do using the resources at our old institution,” he said. “It’s phenomenal.”

Quantum Calculations

X-ray radiation is the most frequently used form of radiation therapy, but a new treatment is emerging that uses a beam of protons to kill cancer cells with minimum damage on surrounding tissues.

“As happens in cancer therapy, we know empirically that it works, but we don’t know why,” said Jorge A. Morales, a professor of chemistry at Texas Tech University and a leading proponent of the computational analysis of proton therapy. “To do experiments with human subjects is dangerous, so the best way is through computer simulation.”

Computational experiments can mimic the dynamics of the proton-cell interactions without causing damage to a patient and can reveal what happens when the proton beam and cells collide from start to finish, with atomic-level accuracy. Morales has been simulating proton-cell chemical reactions using quantum dynamics models on TACC’s Stampede supercomputer to investigate the fundamentals of the process.

His studies, reported in PLOS One in March 2017, as well as in Molecular Physics, and Chemical Physics Letters (2015 and 2014 respectively), have determined the basic byproducts of protons colliding with water within the cell, and with nucleotides and clusters of DNA bases – the basic units of DNA. The studies shed light on how the protons and their water radiolysis products damage DNA.

Though fundamental in nature, the insights and data that Morales’ simulations produce help researchers understand proton cancer therapy at the quantum level, and help modulate factors like dosage and beam direction.

“These simulations will bring about a unique way to understand and control proton cancer therapy that, at a very low cost, will help to drastically improve the treatment of cancer patients without risking human subjects,” Morales said.

Computational Treatment Planning

Wei Liu, a researcher at the Mayo Clinic, also studies proton therapy, but he looks at the treatment from a clinical perspective.

In comparison with current radiation procedures, proton therapy saves healthy tissue in front of and behind the tumor. It is particularly effective when irradiating tumors near sensitive organs where stray beams can be particularly damaging.

However, the pinpoint accuracy required by the protein beam, which is its greatest advantage, means that it must be precisely calibrated and that discrepancies from the ideal (whether from device, human error or even patient breathing) must be taken into consideration.

Writing in Medical Physics in January 2017, Liu and his collaborators showed that their “chance-constrained model” was better at sparing organs at risk than current methods.

“Each time, we try to mathematically generate a good plan,” he said. “There are 25,000 variables or more, so generating a plan that is robust to these mistakes and can still get the proper dose distribution to the tumor is a large-scale optimization problem.”

The researchers used the Lonestar5 supercomputer at TACC to generate treatment plans that minimize the risk and uncertainties involved in proton beam therapy.

“It’s very computationally expensive to generate a plan in a reasonable timeframe,” he continued. “Without a supercomputer, we can do nothing.”

Computational Trial Design

Another way researchers use TACC’s advanced computers is to design clinical trials that can better determine which combination of dosages will be most effective, specifically for the biological agents used in immunotherapy, which work very differently from chemotherapy and radiation.

Writing in the Journal of the Royal Statistics Society Series C (Applied Statistics), Chunyan Cai, assistant professor of biostatistics at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) described her efforts using Lonestar5 to identify biologically optimal dose combinations for agents that target the PI3K/AKT/mTOR signaling pathway, which has been associated with several genetic aberrations related to the promotion of cancer.

Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Immunotherapy fights cancer by supercharging the immune system’s natural defenses (include T-cells) or contributing additional immune elements that can help the body kill cancer cells. HPC is helping researchers better understand how immunotherapeutic agents can be used effectively [Courtesy: NIAID]
“Our research is motivated by a drug combination trial at MD Anderson Cancer Center for patients diagnosed with relapsed lymphoma,” Cai said. “The trial combined two novel biological agents that target two different components in the PI3K/AKT/mTOR signaling pathway.”

They investigated six different dose-toxicity and dose-efficacy scenarios and carried out 2,000 simulated trials for each of the designs.

Based on those simulations, she concluded that “the design proposed has desirable operating characteristics in identifying the biologically optimal dose combination under various patterns of dose–toxicity and dose–efficacy relationships.”

The research is leading to new, safer and more effective ways to test combinations of immunotherapeutic agents.

Machine Learning

A final, and truly radical, way that researchers are using HPC for cancer research is through the application of machine and deep learning.

The Eberlin research group at UT Austin develops clinical applications of ambient mass spectrometry for cancer diagnosis. They create tools and techniques to assist surgeons in distinguishing between normal and cancer tissue during tumor resection operations.

To do so, they have had to develop statistical methods that can analyze and interpret large amount of mass spectrometry data gathered from clinical samples.

Jonathan Young, a post-doctoral research in the group, is building machine learning classifiers to reliably predict whether a given tissue sample is cancer or normal, and if it is indeed cancer, which specific subtype the tumor belongs to.

Young uses the Maverick system at TACC, which contains a large number of NVIDIA GPUs, to develop and implement the machine learning algorithms. “The large memory capacity of Maverick is well suited for our extensive datasets, and the parallelization capability will aid in parameter sweeps during the training of classifiers,” Young said.

Young will present his work at the American Society for Mass Spectrometry (ASMS) Annual Conference this June.

Another example of the application of machine learning to cancer can be found in the work of Daniel Lobo, an assistant professor of biology and computer science at the University of Maryland, Baltimore County (UMBC). He is using machine learning to map out the cellular communication networks that underlie cancer, and to design methods to disrupt them.

In their January 2017 paper in Scientific Reports, Lobo and collaborators showed that machine learning can uncover the cellular networks that determine pigmentation in tadpoles and reverse-engineering never-before-seen coloration. Their work was facilitated by Stampede, which enabled the team to run billions of simulations to identify models of the cellular network and the means of altering it.

Lobo’s lab is applying the method to cancer research to determine what type of interventions might stop metastasis in its tracks without damaging other cells.

“Traditional approaches like chemotherapy attack the cells that grow the most, but leave cells that are signaling others to grow and that may be the most important,” Lobo says. “We’re using machine learning to find out the communication networks between these cells and hopefully to discover a treatment that can cause the tumor to collapse.”

“Getting a true understanding, given the complexity of the information, without some assistance from machine learning, is probably hopeless,” said Michael Levin, Lobo’s collaborator. “I think it’s inevitable that we use machine learning to enrich scientific and biomedical discovery.”

From patient-specific treatments to immunology to drug discovery, advanced computing is accelerating the basic and applied science underlying our understanding of cancer and the development and application of cancer treatments.

If scientists are the rocket in the cancer moonshot, HPC processing power is the jet fuel.

About the Author

Aaron Dubrow joined TACC in October 2007 as the Science and Technology Writer with the responsibility of reporting on the myriad of research and development projects undertaken by TACC.

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industy updates delivered to you every week!

University of Chicago Researchers Generate First Computational Model of Entire SARS-CoV-2 Virus

January 15, 2021

Over the course of the last year, many detailed computational models of SARS-CoV-2 have been produced with the help of supercomputers, but those models have largely focused on critical elements of the virus, such as its Read more…

By Oliver Peckham

Pat Gelsinger Returns to Intel as CEO

January 14, 2021

The Intel board of directors has appointed a new CEO. Intel alum Pat Gelsinger is leaving his post as CEO of VMware to rejoin the company that he parted ways with 11 years ago. Gelsinger will succeed Bob Swan, who will remain CEO until Feb. 15. Gelsinger previously spent 30 years... Read more…

By Tiffany Trader

Roar Supercomputer to Support Naval Aircraft Research

January 14, 2021

One might not think “aircraft” when picturing the U.S. Navy, but the military branch actually has thousands of aircraft currently in service – and now, supercomputing will help future naval aircraft operate faster, Read more…

By Staff report

DOE and NOAA Extend Computing Partnership, Plan for New Supercomputer

January 14, 2021

The National Climate-Computing Research Center (NCRC), hosted by Oak Ridge National Laboratory (ORNL), has been supporting the climate research of the National Oceanic and Atmospheric Administration (NOAA) for the last 1 Read more…

By Oliver Peckham

Using Micro-Combs, Researchers Demonstrate World’s Fastest Optical Neuromorphic Processor for AI

January 13, 2021

Neuromorphic computing, which uses chips that mimic the behavior of the human brain using virtual “neurons,” is growing in popularity thanks to high-profile efforts from Intel and others. Now, a team of researchers l Read more…

By Oliver Peckham

AWS Solution Channel

Now Available – Amazon EC2 C6gn Instances with 100 Gbps Networking

Amazon EC2 C6gn instances powered by AWS Graviton2 processors are now available!

Compared to C6g instances, this new instance type provides 4x higher network bandwidth, 4x higher packet processing performance, and 2x higher EBS bandwidth. Read more…

Intel® HPC + AI Pavilion

Intel Keynote Address

Intel is the foundation of HPC – from the workstation to the cloud to the backbone of the Top500. At SC20, Intel’s Trish Damkroger, VP and GM of high performance computing, addresses the audience to show how Intel and its partners are building the future of HPC today, through hardware and software technologies that accelerate the broad deployment of advanced HPC systems. Read more…

Honing In on AI, US Launches National Artificial Intelligence Initiative Office

January 13, 2021

To drive American leadership in the field of AI into the future, the National Artificial Intelligence Initiative Office has been launched by the White House Office of Science and Technology Policy (OSTP). The new agen Read more…

By Todd R. Weiss

Pat Gelsinger Returns to Intel as CEO

January 14, 2021

The Intel board of directors has appointed a new CEO. Intel alum Pat Gelsinger is leaving his post as CEO of VMware to rejoin the company that he parted ways with 11 years ago. Gelsinger will succeed Bob Swan, who will remain CEO until Feb. 15. Gelsinger previously spent 30 years... Read more…

By Tiffany Trader

Julia Update: Adoption Keeps Climbing; Is It a Python Challenger?

January 13, 2021

The rapid adoption of Julia, the open source, high level programing language with roots at MIT, shows no sign of slowing according to data from Julialang.org. I Read more…

By John Russell

Intel ‘Ice Lake’ Server Chips in Production, Set for Volume Ramp This Quarter

January 12, 2021

Intel Corp. used this week’s virtual CES 2021 event to reassert its dominance of the datacenter with the formal roll out of its next-generation server chip, the 10nm Xeon Scalable processor that targets AI and HPC workloads. The third-generation “Ice Lake” family... Read more…

By George Leopold

Researchers Say It Won’t Be Possible to Control Superintelligent AI

January 11, 2021

Worries about out-of-control AI aren’t new. Many prominent figures have suggested caution when unleashing AI. One quote that keeps cropping up is (roughly) th Read more…

By John Russell

AMD Files Patent on New GPU Chiplet Approach

January 5, 2021

Advanced Micro Devices is accelerating the GPU chiplet race with the release of a U.S. patent application for a device that incorporates high-bandwidth intercon Read more…

By George Leopold

Programming the Soon-to-Be World’s Fastest Supercomputer, Frontier

January 5, 2021

What’s it like designing an app for the world’s fastest supercomputer, set to come online in the United States in 2021? The University of Delaware’s Sunita Chandrasekaran is leading an elite international team in just that task. Chandrasekaran, assistant professor of computer and information sciences, recently was named... Read more…

By Tracey Bryant

Intel Touts Optane Performance, Teases Next-gen “Crow Pass”

January 5, 2021

Competition to leverage new memory and storage hardware with new or improved software to create better storage/memory schemes has steadily gathered steam during Read more…

By John Russell

Farewell 2020: Bleak, Yes. But a Lot of Good Happened Too

December 30, 2020

Here on the cusp of the new year, the catchphrase ‘2020 hindsight’ has a distinctly different feel. Good riddance, yes. But also proof of science’s power Read more…

By John Russell

Esperanto Unveils ML Chip with Nearly 1,100 RISC-V Cores

December 8, 2020

At the RISC-V Summit today, Art Swift, CEO of Esperanto Technologies, announced a new, RISC-V based chip aimed at machine learning and containing nearly 1,100 low-power cores based on the open-source RISC-V architecture. Esperanto Technologies, headquartered in... Read more…

By Oliver Peckham

Azure Scaled to Record 86,400 Cores for Molecular Dynamics

November 20, 2020

A new record for HPC scaling on the public cloud has been achieved on Microsoft Azure. Led by Dr. Jer-Ming Chia, the cloud provider partnered with the Beckman I Read more…

By Oliver Peckham

NICS Unleashes ‘Kraken’ Supercomputer

April 4, 2008

A Cray XT4 supercomputer, dubbed Kraken, is scheduled to come online in mid-summer at the National Institute for Computational Sciences (NICS). The soon-to-be petascale system, and the resulting NICS organization, are the result of an NSF Track II award of $65 million to the University of Tennessee and its partners to provide next-generation supercomputing for the nation's science community. Read more…

Is the Nvidia A100 GPU Performance Worth a Hardware Upgrade?

October 16, 2020

Over the last decade, accelerators have seen an increasing rate of adoption in high-performance computing (HPC) platforms, and in the June 2020 Top500 list, eig Read more…

By Hartwig Anzt, Ahmad Abdelfattah and Jack Dongarra

Aurora’s Troubles Move Frontier into Pole Exascale Position

October 1, 2020

Intel’s 7nm node delay has raised questions about the status of the Aurora supercomputer that was scheduled to be stood up at Argonne National Laboratory next year. Aurora was in the running to be the United States’ first exascale supercomputer although it was on a contemporaneous timeline with... Read more…

By Tiffany Trader

Julia Update: Adoption Keeps Climbing; Is It a Python Challenger?

January 13, 2021

The rapid adoption of Julia, the open source, high level programing language with roots at MIT, shows no sign of slowing according to data from Julialang.org. I Read more…

By John Russell

10nm, 7nm, 5nm…. Should the Chip Nanometer Metric Be Replaced?

June 1, 2020

The biggest cool factor in server chips is the nanometer. AMD beating Intel to a CPU built on a 7nm process node* – with 5nm and 3nm on the way – has been i Read more…

By Doug Black

Programming the Soon-to-Be World’s Fastest Supercomputer, Frontier

January 5, 2021

What’s it like designing an app for the world’s fastest supercomputer, set to come online in the United States in 2021? The University of Delaware’s Sunita Chandrasekaran is leading an elite international team in just that task. Chandrasekaran, assistant professor of computer and information sciences, recently was named... Read more…

By Tracey Bryant

Leading Solution Providers

Contributors

Top500: Fugaku Keeps Crown, Nvidia’s Selene Climbs to #5

November 16, 2020

With the publication of the 56th Top500 list today from SC20's virtual proceedings, Japan's Fugaku supercomputer – now fully deployed – notches another win, Read more…

By Tiffany Trader

Texas A&M Announces Flagship ‘Grace’ Supercomputer

November 9, 2020

Texas A&M University has announced its next flagship system: Grace. The new supercomputer, named for legendary programming pioneer Grace Hopper, is replacing the Ada system (itself named for mathematician Ada Lovelace) as the primary workhorse for Texas A&M’s High Performance Research Computing (HPRC). Read more…

By Oliver Peckham

At Oak Ridge, ‘End of Life’ Sometimes Isn’t

October 31, 2020

Sometimes, the old dog actually does go live on a farm. HPC systems are often cursed with short lifespans, as they are continually supplanted by the latest and Read more…

By Oliver Peckham

Nvidia and EuroHPC Team for Four Supercomputers, Including Massive ‘Leonardo’ System

October 15, 2020

The EuroHPC Joint Undertaking (JU) serves as Europe’s concerted supercomputing play, currently comprising 32 member states and billions of euros in funding. I Read more…

By Oliver Peckham

Gordon Bell Special Prize Goes to Massive SARS-CoV-2 Simulations

November 19, 2020

2020 has proven a harrowing year – but it has produced remarkable heroes. To that end, this year, the Association for Computing Machinery (ACM) introduced the Read more…

By Oliver Peckham

Nvidia-Arm Deal a Boon for RISC-V?

October 26, 2020

The $40 billion blockbuster acquisition deal that will bring chipmaker Arm into the Nvidia corporate family could provide a boost for the competing RISC-V architecture. As regulators in the U.S., China and the European Union begin scrutinizing the impact of the blockbuster deal on semiconductor industry competition and innovation, the deal has at the very least... Read more…

By George Leopold

Intel Xe-HP GPU Deployed for Aurora Exascale Development

November 17, 2020

At SC20, Intel announced that it is making its Xe-HP high performance discrete GPUs available to early access developers. Notably, the new chips have been deplo Read more…

By Tiffany Trader

HPE, AMD and EuroHPC Partner for Pre-Exascale LUMI Supercomputer

October 21, 2020

Not even a week after Nvidia announced that it would be providing hardware for the first four of the eight planned EuroHPC systems, HPE and AMD are announcing a Read more…

By Oliver Peckham

  • arrow
  • Click Here for More Headlines
  • arrow
Do NOT follow this link or you will be banned from the site!
Share This